BR0013905A - Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag - Google Patents

Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag

Info

Publication number
BR0013905A
BR0013905A BR0013905-0A BR0013905A BR0013905A BR 0013905 A BR0013905 A BR 0013905A BR 0013905 A BR0013905 A BR 0013905A BR 0013905 A BR0013905 A BR 0013905A
Authority
BR
Brazil
Prior art keywords
treatment
prevention
individual
inducing
drug
Prior art date
Application number
BR0013905-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Pnina Fishman
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13186499A external-priority patent/IL131864A0/xx
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of BR0013905A publication Critical patent/BR0013905A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0013905-0A 1999-09-10 2000-09-08 Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag BR0013905A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13186499A IL131864A0 (en) 1999-09-10 1999-09-10 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
IL13368099A IL133680A0 (en) 1999-09-10 1999-12-23 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
PCT/IL2000/000550 WO2001019360A2 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Publications (1)

Publication Number Publication Date
BR0013905A true BR0013905A (pt) 2003-07-15

Family

ID=26323880

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013905-0A BR0013905A (pt) 1999-09-10 2000-09-08 Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag

Country Status (19)

Country Link
US (2) US7064112B1 (enExample)
EP (1) EP1261322B1 (enExample)
JP (2) JP4980530B2 (enExample)
KR (2) KR100584797B1 (enExample)
CN (1) CN100358512C (enExample)
AU (1) AU782826B2 (enExample)
BR (1) BR0013905A (enExample)
CA (1) CA2384111C (enExample)
DE (1) DE60037277T2 (enExample)
DK (1) DK1261322T3 (enExample)
ES (1) ES2296637T3 (enExample)
HK (1) HK1052653B (enExample)
HU (1) HU226913B1 (enExample)
IL (1) IL133680A0 (enExample)
MX (1) MXPA02002546A (enExample)
PL (1) PL199852B1 (enExample)
PT (1) PT1261322E (enExample)
RU (1) RU2239455C2 (enExample)
WO (1) WO2001019360A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
CN1234358C (zh) 2000-06-21 2006-01-04 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物
EP1365776B1 (en) * 2001-01-16 2005-04-13 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20040204481A1 (en) * 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7049303B2 (en) * 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
ATE371191T1 (de) * 2002-10-22 2007-09-15 Can Fite Biopharma Ltd Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
EP1753760B1 (en) 2004-05-24 2008-01-02 F.Hoffmann-La Roche Ag 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
DE602005020286D1 (de) 2004-05-26 2010-05-12 Inotek Pharmaceuticals Corp Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
BRPI0515506A (pt) 2004-09-20 2008-07-29 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso dos mesmos
US20060159627A1 (en) * 2004-10-15 2006-07-20 Dewan Zeng Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CN101056857B (zh) 2004-11-05 2010-12-01 弗·哈夫曼-拉罗切有限公司 异烟酸衍生物的制备方法
MX2007005525A (es) * 2004-11-08 2007-07-05 Can Fite Biopharma Ltd Tratamiento terapeutico de resorcion ose acelerada.
CA2586420A1 (en) * 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
KR100973609B1 (ko) 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
CA2623721C (en) 2005-09-27 2014-05-13 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
AU2006320578B2 (en) 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
KR101037095B1 (ko) * 2006-01-27 2011-05-26 캔-파이트 바이오파마 리미티드 건성안 장애의 치료를 위한 아데노신 ａ3 수용체 아고니스트
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008045330A2 (en) * 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure
GB0625100D0 (en) * 2006-12-15 2007-01-24 Univ Murcia Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
TW200914048A (en) * 2007-07-17 2009-04-01 Combinatorx Inc Combinations for the treatment of B-cell proliferative disorders
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2010027935A1 (en) * 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
AU2010250759B2 (en) 2009-05-17 2013-03-14 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
EP2456419B1 (en) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
WO2011074903A2 (ko) * 2009-12-17 2011-06-23 이화여자대학교 산학협력단 Ａ3 아데노신 수용체 효능제를 포함하는 약제학적 조성물
EA025415B1 (ru) 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Комбинация, набор и способ снижения внутриглазного давления
KR20130072189A (ko) 2010-03-03 2013-07-01 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈 포도막염의 치료를 위한 ａ3ａｒ 작동약
EP2569325A4 (en) 2010-03-26 2013-10-09 Inotek Pharmaceuticals Corp METHOD FOR REDUCING INNER EYE PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA), CPA DERIVATIVES OR PRODRUGS THEREOF
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1202053A1 (en) * 2012-01-23 2015-09-18 Can-Fite Biopharma Ltd. Treatment of liver conditions
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
ES2627010T3 (es) 2012-07-19 2017-07-26 Janssen Pharmaceutica, N.V. Antagonistas de octahidro-ciclopentapirrolilo de CCR2
BR112015002697A8 (pt) 2012-08-09 2018-01-16 Can Fite Biopharma Ltd uso de ligante de receptor de adenosina a3 (a3ar), ligante de a3ar, e, composição farmacêutica para tratar disfunção sexual em um indivíduo
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
IL254535A0 (en) * 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
EP3749322A4 (en) 2018-02-09 2021-11-17 Astrocyte Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR THE TREATMENT OF ADDICTION AND RELATED DISORDERS
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
DE69428536T2 (de) * 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
GB2289218A (en) * 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
RU2071770C1 (ru) * 1994-12-14 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака шейки матки и яичников
RU2071771C1 (ru) * 1995-01-11 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака молочной железы
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
US6048865A (en) * 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
CA2296485A1 (en) * 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
EP1011608A4 (en) * 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF HEART AND NEUTRAL FAILURE OR DAMAGE RELATED TO ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR CALLED BY THE ADDITION OF SPECIFIC MEDICINES
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
BR0007864A (pt) * 1999-02-01 2001-11-06 Univ Virginia Composto, e, uso de um composto
IL131096A (en) 1999-07-26 2004-09-27 Can Fite Technologies Ltd Method for preparing a composition derived from muscle tissue

Also Published As

Publication number Publication date
KR20020038749A (ko) 2002-05-23
CA2384111A1 (en) 2001-03-22
HU226913B1 (en) 2010-03-01
KR20060036490A (ko) 2006-04-28
CA2384111C (en) 2008-05-27
CN100358512C (zh) 2008-01-02
AU6863400A (en) 2001-04-17
IL133680A0 (en) 2001-04-30
RU2239455C2 (ru) 2004-11-10
PL356469A1 (en) 2004-06-28
DK1261322T3 (da) 2008-04-07
EP1261322A2 (en) 2002-12-04
JP2007204496A (ja) 2007-08-16
WO2001019360A2 (en) 2001-03-22
JP2003514771A (ja) 2003-04-22
US7064112B1 (en) 2006-06-20
WO2001019360A3 (en) 2002-09-19
HUP0203870A2 (hu) 2003-03-28
HUP0203870A3 (en) 2005-07-28
KR100674529B1 (ko) 2007-01-30
HK1052653A1 (zh) 2003-09-26
KR100584797B1 (ko) 2006-06-02
MXPA02002546A (es) 2003-07-21
RU2002109228A (ru) 2004-01-10
PT1261322E (pt) 2008-01-09
ES2296637T3 (es) 2008-05-01
AU782826B2 (en) 2005-09-01
DE60037277D1 (de) 2008-01-10
HK1052653B (zh) 2008-08-01
CN1391468A (zh) 2003-01-15
JP4980530B2 (ja) 2012-07-18
DE60037277T2 (de) 2008-10-09
PL199852B1 (pl) 2008-11-28
US20060084626A1 (en) 2006-04-20
EP1261322B1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
BR0013905A (pt) Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag
BR0014384A (pt) Compostos para o tratamento da isquémia
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
GEP20022804B (en) Erythropoietin Derivatives
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
BR0110420A (pt) Agonistas muscarìnicos
HUP9901807A3 (en) Heterocycle substituted n-acyl benzenesulfonamide derivatives, process for their preparation and their use as prodrug for the preparation of pharmaceutical compositions treating inflammation or inflammation-associated disorders
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
AR010700A1 (es) Derivados de purina sustituidos, procedimiento para su preparacion, su empleo y su agente que los contiene
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR0110049A (pt) Agonista de cxcr4, uso de um agonista de cxcr4, e composição farmacêutica
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
BR9915951A (pt) Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]